-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – STMC-103H in Atopic Dermatitis (Atopic Eczema)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - STMC-103H in Atopic Dermatitis (Atopic Eczema) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.STMC-103H in Atopic Dermatitis (Atopic Eczema) Drug Details:STMC-103H is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TG-4050 in Peritoneal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TG-4050 in Peritoneal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TG-4050 in Peritoneal Cancer Drug Details: TG-4050 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TG-4050 in Fallopian Tube Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TG-4050 in Fallopian Tube Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TG-4050 in Fallopian Tube Cancer Drug Details: TG-4050 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ARB-202 in Bile Duct Cancer (Cholangiocarcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ARB-202 in Bile Duct Cancer (Cholangiocarcinoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.ARB-202 in Bile Duct Cancer (Cholangiocarcinoma) Drug Details:ARB-202 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Agalsidase Beta Biosimilar in Fabry Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Agalsidase Beta Biosimilar in Fabry Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Agalsidase Beta Biosimilar in Fabry DiseaseDrug Details:Agalsidase beta (alpha-galactosidase) biosimilar is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tozorakimab in Acute Respiratory Failure
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Tozorakimab in Acute Respiratory FailureDrug Details: Tozorakimab (MEDI-3506) is under development for the treatment of diabetic kidney...
-
Company Profile
Transgene SA – Company Profile
Transgene SA (Transgene), a subsidiary of Institut Merieux SA, operates as a biotechnology company that includes discovery and development of immunotherapies in the areas of cancer and infectious diseases. It provides products such as TG4050, TG4001, TG600, BT-001 and TG6050. The company’s products therapeutic areas include colorectal cancer (IV), colorectal cancers (IAH), HPV-positive cancers and non-small cell lung cancer. Transgene carries out technology platforms such as myvac and invir.IO. It operates through collaborations with numerous reference clinical centers, university hospitals...
Add to Basket -
Product Insights
Cervical Intraepithelial Neoplasia (CIN) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Cervical Intraepithelial Neoplasia Pipeline Drugs Market Overview Cervical Intraepithelial Neoplasia (CIN), also known as cervical dysplasia is characterized by abnormal appearance of cells on the surface of the cervix. Cervical dysplasia usually occurs in women aging twenty five to thirty five. Most cases of cervical dysplasia are caused by human papilloma virus (HPV). Signs and symptoms include genital warts, abnormal bleeding, spotting after intercourse, vaginal discharge, and low back pain. The CIN pipeline drugs market research report provides comprehensive information...
-
Product Insights
Multiple Myeloma (Kahler Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Multiple Myeloma Pipeline Products Market Report Overview Multiple myeloma is a type of cancer that is caused by malignant plasma cells that proliferate in the bone marrow and produce abnormally high amounts of a special protein. The exact cause of multiple myeloma is not clear. It mainly affects older adults. Symptoms include anemia, bleeding, nerve damage, skin lesions, bone tenderness or pain, and kidney failure. Treatment includes chemotherapy, radiation, immunosuppression, and surgery. The Multiple Myeloma Drugs in Development market research...
-
Product Insights
Ovarian Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Ovarian Cancer Pipeline Drugs Market Overview Ovarian cancer is any cancerous growth that may occur in different parts of the ovary. The majority of ovarian cancers arise from the epithelium (outer lining) of the ovary. Signs and symptoms of ovarian cancer include pelvic discomfort or pain, indigestion, gas or nausea, and changes in bowel habits, such as constipation, loss of appetite, and low back pain. The predisposing factors include age and family history. Treatment includes surgery, chemotherapy, and radiation therapy....